Laekna (HKG:2105) said China's National Medical Products Administration accepted the new drug application for afuresertib (LAE002) to treat certain patients with advanced breast cancer.
The application is supported by positive results from the company's Phase III AFFIRM-205 clinical trial, according to a Wednesday Hong Kong bourse filing.